RAD51B and leiomyoma: We confirmed the expression pattern of several previously highlighted biomarkers (Figure 2A–D), including upregulation of RAD51 paralog B (RAD51B) in leiomyomas with a MED12 mutation (q-value = 6.20 × 10−13, FC = 4.76), upregulation of HMGA2 in leiomyomas with positive staining for HMGA2 (q-value = 4.84 × 10−19, FC = 28.44), upregulation of aldo-keto reductase family 1 member B10 (AKR1B10) in leiomyomas with positive staining for 2SC (q = 1.54 × 10−07, FC = 11.47), and upregulation of zinc finger matrin-type 3 (ZMAT3) in all leiomyoma subtypes (q-value = 2.90 × 10−04, FC = 2.69).